Ceregene Completes Enrollment Of Phase 2 Clinical Trial For Parkinson’s Disease

Ceregene, Inc. announced that the company has completed enrollment of its randomized, controlled, double-blind, Phase 2 clinical trial evaluating CERE-120, a gene therapy product in development for the treatment of Parkinson’s disease. The trial enrolled 58 patients with advanced Parkinson’s disease across nine medical centers in the United States. The company expects to announce results from the trial in late 2008. [click link for full article]

More: continued here

Filed under: Parkinson's Disease on November 18th, 2007